EUVIMEDEUVIMED entdecken
Open Access

Notch4 regulatory T cells and SARS‐CoV‐2 viremia shape COVID19 survival outcome

Mehdi Benamar iD, Peggy S Lai, Ching-Ying Huang, Qian Chen, Fatma Betul Oktelik, Paola Contini, Muyun Wang, Daniel Okin, Elena Crestani, Jason Fong iD, Tsz Man Chan Fion, Merve Nida Gokbak iD und 12 weitere

Allergy · 2025-02 · 80 (2) · 557-569

DOI: 10.1111/all.16333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 03.10.2024. Verfasst von Mehdi Benamar und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: COVID-19, T-Lymphocytes, Regulatory, Viremia, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Deutsche Gesellschaft für Suchtforschung und Suchttherapie, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune dysregulation and SARS‐CoV‐2 plasma viremia have been implicated in fatal COVID‐19 disease. However, how these two factors interact to shape disease outcomes is unclear.

Methods

We carried out viral and immunological phenotyping on a prospective cohort of 280 patients with COVID‐19 presenting to acute care hospitals in Boston, Massachusetts and Genoa, Italy between June 1, 2020 and February 8, 2022. Disease severity, mortality, plasma viremia, and immune dysregulation were assessed. A mouse model of lethal H1N1 influenza infection was used to analyze the therapeutic potential of Notch4 and pyroptosis inhibition in disease outcome.

Results

Stratifying patients based on %Notch4 + Treg cells and/or the presence of plasma viremia identified four subgroups with different clinical trajectories and immune phenotypes. Patients with both high %Notch4 + Treg cells and viremia suffered the most disease severity and 90‐day mortality compared to the other groups even after adjusting for baseline comorbidities. Increased Notch4 and plasma viremia impacted different arms of the immune response in SARS‐CoV‐2 infection. Increased Notch4 was associated with decreased Treg cell amphiregulin expression and suppressive function whereas plasma viremia was associated with increased monocyte cell pyroptosis. Combinatorial therapies using Notch4 blockade and pyroptosis inhibition induced stepwise protection against mortality in a mouse model of lethal H1N1 influenza infection.

Conclusions

The clinical trajectory and survival outcome in hospitalized patients with COVID‐19 is predicated on two cardinal factors in disease pathogenesis: viremia and Notch4 + Treg cells. Intervention strategies aimed at resetting the immune dysregulation in COVID‐19 by antagonizing Notch4 and pyroptosis may be effective in severe cases of viral lung infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19T-Lymphocytes, RegulatoryViremiaSARS-CoV-2Receptor, Notch4HumansAnimalsFemaleMiceMaleMiddle AgedDisease Models, AnimalProspective StudiesAgedPyroptosisAdultInfluenza A Virus, H1N1 Subtype

Stichwörter der Autor:innen

COVID19Notch4pyroptosisregulatory T cellssurvivalviremia

Substanzen

Receptor, Notch4

Autor:innen und Institutionen

  • Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Internal Medicine, Unit of Clinical Immunology and Translational Medicine, University of Genova, Genova, Italy.
  • Clinical Immunology Division, IRCCS-San Martino Hospital, Genoa, Italy.

ORCID-Profile: Mehdi Benamar, Jason Fong, Merve Nida Gokbak, Hani Harb, Claudia Angelini, Talal A Chatila

Förderung

  • NCATS NIH HHS
  • Deutsche Gesellschaft für Suchtforschung und Suchttherapie
  • NIAID NIH HHS
  • Boston Children's Hospital
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Benamar, M., Lai, P. S., Huang, C. Y., Chen, Q., Oktelik, F. B., Contini, P., Wang, M., Okin, D., Crestani, E., Fong, J., Fion, T. M. C., Gokbak, M. N., Harb, H., Phipatanakul, W., Marri, L., Vassallo, C., Guastalla, A., Kim, M., Sui, H. Y., …, & Chatila, T. A. (2025). Notch4 regulatory T cells and SARS‐CoV‐2 viremia shape COVID19 survival outcome. Allergy, 80(2), 557-569. https://doi.org/10.1111/all.16333

Vancouver

Benamar M, Lai PS, Huang CY, Chen Q, Oktelik FB, Contini P, et al. Notch4 regulatory T cells and SARS‐CoV‐2 viremia shape COVID19 survival outcome. Allergy. 2025;80(2):557-569. doi:10.1111/all.16333

BibTeX
@article{Benamar2025,
  author = {Benamar, Mehdi and Lai, Peggy S and Huang, Ching-Ying and Chen, Qian and Oktelik, Fatma Betul and Contini, Paola and Wang, Muyun and Okin, Daniel and Crestani, Elena and Fong, Jason and Fion, Tsz Man Chan and Gokbak, Merve Nida and Harb, Hani and Phipatanakul, Wanda and Marri, Luca and Vassallo, Chiara and Guastalla, Andrea and Kim, Minsik and Sui, Hui-Yu and Berra, Lorenzo and Goldberg, Marcia B and Angelini, Claudia and De Palma, Raffaele and Chatila, Talal A},
  title = {Notch4 regulatory T cells and SARS‐CoV‐2 viremia shape COVID19 survival outcome},
  journal = {Allergy},
  year = {2025},
  volume = {80},
  number = {2},
  pages = {557--569},
  doi = {10.1111/all.16333}
}
Kostenlos starten →